These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35394898)

  • 61. Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules.
    Bandyopadhyay AS; Asturias EJ; O'Ryan M; Oberste MS; Weldon W; Clemens R; Rüttimann R; Modlin JF; Gast C
    Vaccine; 2017 Dec; 35(52):7283-7291. PubMed ID: 29150209
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth.
    Linder N; Handsher R; German B; Sirota L; Bachman M; Zinger S; Mendelson E; Barzilai A
    Arch Dis Child Fetal Neonatal Ed; 2000 Jul; 83(1):F24-7. PubMed ID: 10873167
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study.
    Kim KH; Kim CS; Kim HM; Kim JD; Ma SH; Kim DH; Hwang PH; Han JW; Lee TJ; Kim JH; Karkada N; Mesaros N; Sohn WY; Kim JH
    Hum Vaccin Immunother; 2019; 15(2):317-326. PubMed ID: 30431387
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
    Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
    J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
    Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
    Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immunogenicity and lot-to-lot consistency of booster shot with Sabin inactivated poliomyelitis vaccine in Chinese children aged 18-24 Months: A phase Ⅳ clinical trial.
    Yin Q; Zheng Y; Ying Z; Li J; Jiang Y; Bao W; Dou Y; Pu Y; Lei J; Yang H; Jiang R; Deng Y; Zhao Z; Pu J; Yang J; Li Y; Xu M; Cai W; Che Y; Shi L
    Vaccine; 2024 Mar; 42(8):1973-1979. PubMed ID: 38388236
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
    Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
    Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
    Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Safety, immunogenicity and lot-to-lot consistency of a new Bivalent Oral Polio Vaccine (bOPV) in healthy Infants: Results of a Phase III, observer blind, randomized, controlled clinical study.
    Zaman K; Kingma R; Yunus M; van Straaten I; Mekkes D; Bouwstra X; Gunale B; Kulkarni PS
    Vaccine; 2019 Jul; 37(31):4275-4280. PubMed ID: 31235374
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Needle adapters for intradermal administration of fractional dose of inactivated poliovirus vaccine: Evaluation of immunogenicity and programmatic feasibility in Pakistan.
    Saleem AF; Mach O; Yousafzai MT; Khan A; Weldon WC; Oberste MS; Sutter RW; Zaidi AKM
    Vaccine; 2017 May; 35(24):3209-3214. PubMed ID: 28479178
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
    Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
    Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China.
    Kang G; Tang F; Wang Z; Hu R; Yu J; Gao J
    Hum Vaccin Immunother; 2021 Aug; 17(8):2568-2574. PubMed ID: 33780310
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group.
    Modlin JF; Halsey NA; Thoms ML; Meschievitz CK; Patriarca PA
    J Infect Dis; 1997 Feb; 175 Suppl 1():S228-34. PubMed ID: 9203721
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994.
    Ion-Nedelcu N; Strebel PM; Toma F; Biberi-Moroeanu S; Combiescu M; Persu A; Aubert-Combiescu A; Plotkin SA; Sutter RW
    J Infect Dis; 1997 Feb; 175 Suppl 1():S241-6. PubMed ID: 9203723
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine.
    Zhao T; Li J; Shi H; Ye H; Ma R; Fu Y; Liu X; Li G; Yang X; Zhao Z; Yang J
    Hum Vaccin Immunother; 2021 Aug; 17(8):2560-2567. PubMed ID: 33848232
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial.
    Sun X; Xu Y; Tang F; Xiao Y; Wang Z; Wang B; Zhu X; Yang X; Chen H
    Front Immunol; 2022; 13():905634. PubMed ID: 35958596
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
    Faden H; Modlin JF; Thoms ML; McBean AM; Ferdon MB; Ogra PL
    J Infect Dis; 1990 Dec; 162(6):1291-7. PubMed ID: 2172403
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A comparative study of reactogenicity and immunogenicity of an oral and an inactivated polio vaccine.
    Borcić B; Dobrovsak-Sourek V; Kaić B; Ljubicić M
    Acta Med Croatica; 1998; 52(3):155-8. PubMed ID: 9818437
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy.
    Chen S; Zhao Y; Yang Z; Li Y; Shi H; Zhao T; Yang X; Li J; Li G; Wang J; Ying Z; Yang J
    Hum Vaccin Immunother; 2022 Dec; 18(1):2024063. PubMed ID: 35044877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.